Navigation Links
Alzheimer's Drug Shows Promise in Early Trial
Date:7/18/2012

WEDNESDAY, July 18 (HealthDay News) -- Researchers say an investigational drug helped improve memory, language, attention and other mental skills in people with early Alzheimer's disease.

The study was funded by EnVivo Pharmaceuticals, which is developing the drug, dubbed EVP-6124. The results are to be presented Wednesday at the annual meeting of the Alzheimer's Association in Vancouver.

The study involved 409 patients with mild to moderate Alzheimer's disease who were either being treated with the drugs donepezil (Aricept) or rivastigmine (Exelon) or were receiving no treatment.

During the six-month, phase 2 trial, patients took either a placebo or one of three different doses of EVP-6124.

After 23 weeks of treatment, the patients in the high-dose group showed statistically significant benefits on tests of mental function compared to those taking the dummy pill. Some patients in the medium- and high-dose groups did experience mild to moderate gastrointestinal side effects, the team added.

"In our study, EVP-6124 provided significant benefits for people with mild to moderate Alzheimer's whether they were on currently approved therapy or not," Dr. Dana Hilt, senior vice president of clinical development and chief medical officer of EnVivo, said in an Alzheimer's Association news release.

The authors explain that EVP-6124 belongs to a family of drugs called alpha-7 nicotinic agonists, which amplify the effects of acetylcholine, a brain chemical that's essential for normal brain and memory function. People with Alzheimer's disease have greatly reduced levels of acetylcholine.

Currently, there are no effective treatments to fight Alzheimer's disease, although certain drugs may temporarily ameliorate symptoms.

For that reason, the new study "is potentially interesting, as there is a need for better symptomatic treatment of Alzheimer's disease," said Peter Davies, director of the Litwin Zucker Research Center for the Study of Alzheimer's Disease at the Feinstein Institute for Medical Research in New Hyde Park, N.Y.

He pointed out that the mechanism behind the new drug is not altogether novel. "Treating the deficiency of acetylcholine is the basis for the already approved drugs Aricept, Exelon and Razodyne," Davies said. "This drug does the same thing, but in a different way. The other drugs act to reduce the breakdown of acetylcholine: this drug mimics the effect of acetylcholine at one of the receptors for this compound."

He said that there are hints that this approach might do more than just ease symptoms, and might attack the underlying illness. But that remains speculative and "further studies do seem to be warranted," Davies said.

Another expert agreed.

"These promising effects are 'symptomatic' (the drug does not slow progression of disease), and the study is relatively small in size," noted Stephen Ferris, director of the Alzheimer's Disease Center and the clinical trials program at NYU Langone Medical Center's Comprehensive Center on Brain Aging in New York City.

Like Davies, Ferris stressed that "if the results can be confirmed in a larger trial, the drug would be an important addition to current Alzheimer treatments."

Findings presented at medical meeting are typically considered preliminary until published in a peer-reviewed journal.

More information

The U.S. National Institute on Aging has more about Alzheimer's disease medications.

-- Robert Preidt

SOURCES: Peter Davies, Ph.D., director, Litwin Zucker Research Center for the Study of Alzheimer's Disease, Feinstein Institute for Medical Research, New Hyde Park, N.Y.; Steven H. Ferris, Ph.D., Friedman Professor and director, Alzheimer's Disease Center and the clinical trials program, Comprehensive Center on Brain Aging, NYU Langone Medical Center, New York City; Alzheimer's Association, news release, July 18, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Wellesley study shows income inequality a key factor in high US teen births
2. Invasive heart test being dramatically overused, Stanford study shows
3. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
4. Lung Cancer Screening Might Pay Off, Analysis Shows
5. Nonsurgical Method to Measure Brain Pressure Shows Promise
6. BMC study shows diverting passengers to elevators could help reduce falls at Logan Airport
7. Study Shows New Option for Kids With Tough-to-Treat Leukemia
8. Politics May Get in the Way of Empathy, Research Shows
9. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
10. Experimental Pill for Multiple Sclerosis Shows Promise
11. Mechanical tissue resuscitation technology shows promise
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Alzheimer's Drug Shows Promise in Early Trial
(Date:5/4/2016)... ... , ... Nike Rugby Camp's success is due in large part to Ethan ... Rugby Camps and current Nike Camp director, has offered an all abilities rugby camp ... excited for our eighth summer here in San Diego,” says Willis. "We take great ...
(Date:5/4/2016)... ... , ... Hight-Doland Insurance Agency’s new community involvement program which serves families of ... of Southwest Louisiana to help provide positive mentoring for local youth. Donations to this ... of Southwest Louisiana has been helping to guide the area’s youth for over 30 ...
(Date:5/4/2016)... ... ... May kicked off with Melanoma Monday , a multi-agency effort to raise ... encouraging her patients, as well as residents all around Dallas, Cleburne, Irving, and Plano, ... in the future. , The dermatology-specific awareness month ends with “Don’t Fry Day,” established ...
(Date:5/4/2016)... Diego, California (PRWEB) , ... May 04, 2016 ... ... wearable technology that is transforming breastfeeding for nursing mothers. The company’s patented technology, ... intake while breastfeeding. Today, the company announced that the technology is now available ...
(Date:5/4/2016)... ... May 04, 2016 , ... Francesca Loparco, Co-Founder of Queen City Dream Cars, ... same-day LASIK procedure at Christenbury Eye Center. The entrepreneur struggled with her ... surgery the same day as her in-office consultation and eye exam. Francesca’s eyesight was ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... May 3, 2016 BioNovus Innovations LLC ... for Advancing Medical Innovation (IAMI) today announced a ... diagnostics and medical devices. An agreement ... rights to license, develop and commercialize medical innovations ... "This partnership represents a significant advance in ...
(Date:5/3/2016)... ACME Markets, Delaware ... Delaware County Councilman Dave White announced ... ACME pharmacies across Delaware County ... Prevention (CDC), naloxone has saved 26,463 lives nationwide over the past ... Delaware County were authorized to administer naloxone to overdose ...
(Date:5/3/2016)... FLINT, Mich. , May 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today ... The company released a video of two patients who tell their personal story and encourage ... hepatitis.   Meet Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
Breaking Medicine Technology: